BSX vs EW vs SYK
161 measures in 16 categories, one definition each, computed from filings and market data.
BSX66.6
Boston Scientific Corporation
Healthcare · Medical - Devices
$44.39 +0.57%$64.3B mkt cap
Score DNA
EW64.7
Edwards Lifesciences Corporation
Healthcare · Medical - Devices
$86.60 −1.70%$49.9B mkt cap
Score DNA
Price, rebased to 100 three years ago
BSX EW SYK · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Insider open-market buys, 180d | 10 | 0 | 0 |
| Insider $ bought, 180d | $10.04M | — | — |
| Congress purchases, 180d | 15 | 2 | 1 |
| Last Congress purchase | 2026-08-18 | 2026-05-01 | 2026-09-04 |
| 13F net change in holders | — | +46 | −37 |
| ETFs adding shares, 30d | 1,212 | 1,345 | 1,328 |
| ETFs trimming, 30d | 1,059 | 1,066 | 980 |
| Net ETF funds, 30d | +153 | +279 | +348 |
Valuation
16 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| P/E (TTM) | 17.5x
19th
|
49.7x
89th
|
30.3x
56th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.30
7th
|
— | 2.75
80th
|
| Price / sales | 3.1x
45th
|
7.7x
82nd
|
4.4x
72nd
|
| Price / book | 2.6x
41st
|
4.7x
61st
|
4.7x
62nd
|
| Price / tangible book | — | 7.2x
54th
|
— |
| Price / free cash flow | 17.7x
25th
|
34.8x
69th
|
24.0x
44th
|
| Price / operating cash flow | 14.2x
26th
|
29.0x
70th
|
20.5x
53rd
|
| Enterprise value | $76.4B
95th
|
$46.4B
93rd
|
$124.5B
97th
|
| EV / sales | 3.6x
55th
|
7.1x
82nd
|
4.8x
73rd
|
| EV / EBITDA | 13.2x
39th
|
29.3x
76th
|
18.6x
50th
|
| EV / EBIT | 17.4x
27th
|
32.7x
73rd
|
22.9x
45th
|
| EV / free cash flow | 21.1x
25th
|
32.3x
56th
|
26.5x
47th
|
| Earnings yield | 5.7%
92nd
|
2.0%
60th
|
3.3%
75th
|
| FCF yield | 5.6%
85th
|
2.9%
58th
|
4.2%
73rd
|
| Operating cash flow yield | 7.0%
82nd
|
3.4%
50th
|
4.9%
62nd
|
| Graham number (per share) | $30.54
37th
|
$26.83
30th
|
$116.22
93rd
|
Profitability (TTM)
12 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Gross margin | 71.2%
73rd
|
78.0%
87th
|
65.2%
52nd
|
| EBITDA margin | 27.6%
92nd
|
24.3%
83rd
|
25.9%
87th
|
| Operating margin | 21.5%
92nd
|
28.1%
97th
|
22.0%
93rd
|
| EBIT margin | 20.9%
87th
|
21.8%
92nd
|
21.1%
88th
|
| Net margin | 17.5%
93rd
|
15.4%
90th
|
14.4%
87th
|
| NOPAT margin | 20.4%
93rd
|
19.4%
92nd
|
16.0%
85th
|
| FCF margin | 17.3%
82nd
|
22.0%
93rd
|
18.2%
83rd
|
| Operating cash flow margin | 21.6%
88th
|
26.4%
95th
|
21.4%
85th
|
| R&D / revenue | 10.3%
53rd
|
16.7%
73rd
|
6.4%
31st
|
| SG&A / revenue | 34.1%
28th
|
33.8%
25th
|
34.0%
27th
|
| Stock comp / revenue | 0.8%
13th
|
2.6%
47th
|
1.0%
15th
|
| Effective tax rate | 5.0%
5th
|
31.0%
91st
|
27.6%
88th
|
Returns on capital
11 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| ROE (on average equity) | 15.5%
85th
|
9.5%
66th
|
16.5%
86th
|
| ROA | 8.5%
82nd
|
7.3%
77th
|
7.9%
80th
|
| ROIC | 11.6%
71st
|
17.9%
85th
|
11.6%
73rd
|
| ROCE | 11.3%
78th
|
11.5%
80th
|
13.2%
87th
|
| Return on tangible assets | 10.1%
82nd
|
10.4%
83rd
|
11.6%
87th
|
| Cash ROIC (OCF / invested capital) | 12.2%
66th
|
24.3%
85th
|
15.6%
69th
|
| Gross profitability (GP / assets) | 33.0%
43rd
|
36.6%
52nd
|
35.1%
47th
|
| ROIC, 3-yr average | 8.2%
71st
|
28.3%
96th
|
8.7%
73rd
|
| ROIC, 5-yr average | 6.4%
63rd
|
45.2%
96th
|
10.0%
71st
|
| ROE, 5-yr average | 9.0%
71st
|
23.0%
96th
|
15.1%
81st
|
| Incremental ROIC | 61.2%
71st
|
— | 328.7%
92nd
|
Growth
17 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Revenue growth (TTM YoY) | 13.5%
55th
|
14.6%
59th
|
8.5%
39th
|
| Revenue growth (QoQ) | 4.6%
30th
|
5.6%
40th
|
9.5%
58th
|
| Revenue CAGR, 3 yr | 16.1%
66th
|
6.3%
30th
|
9.9%
43rd
|
| Revenue CAGR, 5 yr | 13.4%
54th
|
5.7%
23rd
|
9.7%
38th
|
| Gross profit CAGR, 3 yr | 22.0%
79th
|
6.4%
25th
|
13.1%
56th
|
| Operating income CAGR, 3 yr | 31.6%
72nd
|
4.4%
28th
|
12.8%
52nd
|
| Net income growth (TTM YoY) | 46.6%
67th
|
-75.8%
4th
|
27.8%
62nd
|
| Net income CAGR, 3 yr | 59.0%
85th
|
-10.2%
15th
|
11.2%
45th
|
| EPS growth (TTM YoY) | 47.4%
67th
|
-75.3%
4th
|
27.9%
62nd
|
| EPS CAGR, 3 yr | 58.0%
85th
|
-8.6%
10th
|
11.0%
35th
|
| EPS CAGR, 5 yr | 46.5%
95th
|
-5.6%
15th
|
12.1%
65th
|
| FCF growth (TTM YoY) | 9.5%
40th
|
135.8%
83rd
|
16.8%
50th
|
| FCF CAGR, 3 yr | 36.5%
58th
|
28.1%
46th
|
24.8%
42nd
|
| Operating cash flow CAGR, 3 yr | 28.7%
65th
|
22.3%
61st
|
22.2%
58th
|
| Book value CAGR, 3 yr | 10.3%
59th
|
20.7%
86th
|
11.2%
63rd
|
| Dividend CAGR, 3 yr | — | — | 1.5%
12th
|
| Sustainable growth rate | 15.5%
78th
|
9.5%
41st
|
10.7%
48th
|
Margin history & stability
7 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Gross margin, 3-yr average | 65.5%
53rd
|
78.5%
89th
|
62.9%
45th
|
| Operating margin, 3-yr average | 18.0%
91st
|
27.2%
98th
|
22.0%
94th
|
| Net margin, 3-yr average | 14.3%
89th
|
38.8%
100th
|
14.3%
87th
|
| FCF margin, 3-yr average | 15.6%
85th
|
14.3%
81st
|
16.1%
89th
|
| Revenue stability (0-1) | 0.95
58th
|
0.77
28th
|
0.99
92nd
|
| Earnings stability (0-1) | 0.92
94th
|
0.07
13th
|
0.81
85th
|
| Margin stability (0-1) | 0.93
21st
|
0.98
94th
|
0.97
68th
|
Liquidity (latest quarter)
7 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Cash & short-term investments | $539.0M
78th
|
$4.3B
97th
|
$3.5B
95th
|
| Net cash (− = net debt) | −$12.1B
3rd
|
$3.5B
100th
|
−$11.5B
5th
|
| Working capital | $1.5B
83rd
|
$5.3B
95th
|
$7.7B
98th
|
| Current ratio | 1.24
7th
|
4.52
68th
|
2.16
33rd
|
| Quick ratio | 0.74
7th
|
3.77
70th
|
1.33
27th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.08
7th
|
2.82
72nd
|
0.52
30th
|
| Defensive interval (days) | 126 days
8th
|
585 days
83rd
|
236 days
27th
|
Leverage & solvency (latest quarter)
13 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Total debt | $12.6B
95th
|
$704.4M
58th
|
$14.9B
97th
|
| Debt / equity | 0.51
46th
|
0.07
21st
|
0.62
56th
|
| Net debt / equity | 0.48
61st
|
−0.33
26th
|
0.48
60th
|
| Debt / assets | 27.9%
50th
|
5.1%
18th
|
31.2%
58th
|
| Debt / capital | 33.6%
46th
|
6.2%
21st
|
38.4%
56th
|
| Debt / EBITDA | 2.18
42nd
|
0.45
16th
|
2.23
45th
|
| Net debt / EBITDA | 2.08
50th
|
−2.24
8th
|
1.71
45th
|
| Interest coverage (EBIT / interest) | 12.1x
83rd
|
— | 6.6x
77th
|
| Cash interest coverage | 12.5x
85th
|
— | 6.7x
71st
|
| Debt payback (years of OCF) | 2.8 yrs
44th
|
0.4 yrs
14th
|
2.7 yrs
40th
|
| Liabilities / assets | 44.3%
40th
|
22.7%
17th
|
50.0%
53rd
|
| IS credit model rating | A | AA+ | AA- |
| Implied credit spread (bps) | 150
30th
|
65
8th
|
100
22nd
|
Efficiency
11 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Asset turnover | 0.48
25th
|
0.48
22nd
|
0.55
37th
|
| Fixed asset turnover | 5.09
55th
|
3.35
16th
|
5.77
64th
|
| Inventory turnover | 2.0
64th
|
1.3
19th
|
1.7
41st
|
| Receivables turnover | 7.2
70th
|
8.9
92nd
|
6.7
62nd
|
| Days sales outstanding | 51 days
30th
|
41 days
8th
|
54 days
38th
|
| Days inventory outstanding | 184 days
36th
|
289 days
81st
|
219 days
59th
|
| Days payables outstanding | 66 days
58th
|
47 days
40th
|
63 days
57th
|
| Cash conversion cycle (days) | 169 days
40th
|
283 days
85th
|
210 days
48th
|
| Capex / revenue | 4.3%
62nd
|
4.4%
64th
|
3.2%
45th
|
| Capex / depreciation | 0.64
45th
|
1.73
79th
|
0.66
48th
|
| Operating expense ratio | 49.1%
34th
|
47.7%
29th
|
43.1%
19th
|
Cash flow & earnings quality
7 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Operating cash flow / net income | 1.24
30th
|
1.71
56th
|
1.48
41st
|
| FCF / net income | 0.99
30th
|
1.43
63rd
|
1.26
48th
|
| FCF / operating cash flow | 80.0%
67th
|
83.3%
74th
|
85.1%
76th
|
| Capex / operating cash flow | 20.0%
33rd
|
16.7%
26th
|
14.9%
24th
|
| Accruals ratio | -2.0%
85th
|
-5.2%
50th
|
-3.8%
68th
|
| Sloan accruals ratio | -4.1%
37th
|
-0.2%
55th
|
1.6%
68th
|
| Earnings quality score (0-1) | 1.00
48th
|
0.75
4th
|
1.00
48th
|
Scores & forensic checks
15 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| IS score | 67
85th
|
65
83rd
|
74
93rd
|
| IS profitability | 67
88th
|
64
83rd
|
72
95th
|
| IS growth | 68
68th
|
33
12th
|
64
59th
|
| IS value | 50
73rd
|
36
37th
|
52
77th
|
| IS momentum | 93
93rd
|
64
39th
|
90
86th
|
| IS risk (safety) | 65
42nd
|
100
62nd
|
100
62nd
|
| IS quality | 84
90th
|
82
85th
|
87
95th
|
| IS balance sheet | 61
63rd
|
94
98th
|
63
67th
|
| IS earnings quality | 81
97th
|
75
82nd
|
78
93rd
|
| IS cash flow | 63
73rd
|
89
97th
|
70
77th
|
| Piotroski F-score (0-9) | 8
83rd
|
6
47th
|
9
95th
|
| Altman Z-score | 3.0
50th
|
12.7
88th
|
4.8
63rd
|
| Beneish M-score | −2.49
73rd
|
−2.66
52nd
|
−2.74
30th
|
| Ohlson O-score | −9.32
20th
|
−10.85
8th
|
−9.18
22nd
|
| IS credit score | 71
67th
|
93
88th
|
81
78th
|
Size (TTM)
8 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| Market cap | $64.3B
95th
|
$49.9B
93rd
|
$113.0B
97th
|
| Revenue | $21.0B
95th
|
$6.5B
88th
|
$25.8B
97th
|
| EBITDA | $5.8B
95th
|
$1.6B
88th
|
$6.7B
97th
|
| Net income | $3.7B
95th
|
$1.0B
90th
|
$3.7B
97th
|
| Free cash flow | $3.6B
95th
|
$1.4B
90th
|
$4.7B
97th
|
| Total assets | $45.2B
95th
|
$13.9B
90th
|
$47.9B
97th
|
| Shareholders' equity | $24.9B
97th
|
$10.6B
90th
|
$24.0B
95th
|
| Employees | 59,000
97th
|
16,000
87th
|
56,000
95th
|
Price performance
9 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| 1 day | +0.6% | −1.7% | +0.5% |
| 1 week | +3.9% | +1.6% | +6.3% |
| 1 month | +1.9% | −1.9% | +5.5% |
| 3 months | +1.4% | +1.9% | −7.7% |
| 6 months | −30.9% | +6.9% | −14.2% |
| Year to date | −53.1% | +1.5% | −15.4% |
| 1 year | −54.6% | +18.7% | −20.3% |
| 3 years, cumulative | −12.8% | +21.7% | +15.4% |
| 5 years, cumulative | +2.9% | −20.4% | +16.5% |
Technicals
4 measures| Measure | BSX | EW | SYK |
|---|---|---|---|
| RSI 14 | 52.5 | 49.2 | 58.9 |
| From 52-week high | −58.0% | −10.1% | −24.9% |
| From 52-week low | +7.2% | +19.6% | +10.4% |
| Beta | 0.57 | 0.86 | 0.78 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17